Text: H.R.3964 — 115th Congress (2017-2018)All Information (Except Text)

There is one version of the bill.

Text available as:

Shown Here:
Introduced in House (10/05/2017)


115th CONGRESS
1st Session
H. R. 3964


To amend the Controlled Substances Act to establish additional registration requirements for prescribers of opioids, and for other purposes.


IN THE HOUSE OF REPRESENTATIVES

October 5, 2017

Mr. Roe of Tennessee (for himself, Ms. Kuster of New Hampshire, Mr. MacArthur, Mrs. Radewagen, and Miss González-Colón of Puerto Rico) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned


A BILL

To amend the Controlled Substances Act to establish additional registration requirements for prescribers of opioids, and for other purposes.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. Short title.

This Act may be cited as the “Opioid Addiction Prevention Act of 2017”.

SEC. 2. Registration requirements for prescribers.

Section 303 of the Controlled Substances Act (21 U.S.C. 823) is amended by adding at the end the following:

“(k) (1) The Attorney General shall not register, or renew the registration of, a practitioner under subsection (f) who is licensed under State law to prescribe controlled substances in schedule II, III, or IV, unless the practitioner submits to the Attorney General, for each such registration or renewal request, a certification that the practitioner, during the applicable registration period, will not prescribe, for the initial treatment of acute pain, any schedule II, III, or IV opioid, other than an opioid prescription described in paragraph (3)—

“(A) without firstly or concomitantly prescribing one or more non-opioid analgesics, if there are no contraindications to such analgesics;

“(B) without clearly stating on the prescription the diagnosis for which the opioid is prescribed;

“(C) unless the prescribed opioid dose is the lowest effective dose;

“(D) an extended release or long acting formulation of the opioid; and

“(E) in an amount in excess of the lesser of—

“(i) a 10-day supply (for which no refill is available); or

“(ii) an opioid prescription limit established under State law.

“(2) In this subsection, the term ‘acute pain’—

“(A) means pain with abrupt onset and caused by a discrete injury, surgical procedure, or other illness of limited duration; and

“(B) does not include—

“(i) chronic pain;

“(ii) pain being treated as part of cancer care;

“(iii) hospice or other end-of-life care; or

“(iv) pain being treated as part of palliative care.

“(3) An opioid prescription described in this paragraph is a prescription—

“(A) for a schedule II, III, or IV opioid drug approved by the Food and Drug Administration for an indication for the treatment of addiction; and

“(B) that is for the treatment of addiction.”.